Discussion to: Use of a novel microbiome modulator improves anticancer immunity in a murine model of malignant pleural mesothelioma

Our plain-English summary of Discussion to: Use of a novel microbiome modulator improves anticancer immunity in a murine model of malignant pleural mesothelioma (JTCVS Open, 2024).

The study

• Journal: JTCVS Open
• Published: 2024;18:345-346
• Read it: PubMed · Publisher · Free full text

In plain English

This item is not a research report. It is a printed transcript of the discussion that followed a presentation at the 103rd AATS Annual Meeting. The presentation was of a mouse study of malignant pleural mesothelioma, published separately in the same journal. The study tested a prebiotic distilled from spent brewery grain. In the exchange, the invited discussant, Dr Jessica Donington, said the work had shown a promising result in changing cytotoxic T-cell activity in the mice, but gave no figures. The presenter, Dr Louis-Emmanuel Chriqui, said the mouse model was biphasic, not sarcomatoid, and that BALB mice were the only mice the group had. The presenter mentioned two other models and said the group would like to study a few models to repeat the work. The presenter said combining the prebiotic with CTLA-4 and PD-L1 drugs was the next step, and that the group had focused first on T cells, not B cells. Apart from these brief remarks about the models, the transcript gives no detailed methods and no measured results, and it does not mention asbestos.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Published transcript of a meeting discussion of a separately published mouse study; not a study in itself
• Who was studied: The discussed study used a biphasic mesothelioma model in BALB mice; no numbers of animals are given in this transcript
• Exposure: A prebiotic (microbiome modulator) distilled from spent brewery grain; no asbestos exposure is discussed
• Main results:
  • The invited discussant described the study as showing a promising result in changing cytotoxic T-cell activity in the mouse model. This is the discussant's description; no data are given here.
• Limitations the authors state:
  • The presenter said only BALB mice had been used, and that the group would like to investigate other models to repeat the study
  • The presenter said the work focused first on T cells; B cell populations were raised as a possible next step

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma.

Related studies

• Use of a novel microbiome modulator improves anticancer immunity in a murine model of malignant pleural mesothelioma — C. Gattlen, K.R. Frank, et al. (2024)
• A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma — J. Yuan, S. Kashiwagi, et al. (2014)
• Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma — C.C. Leong, J.V. Marley, et al. (1997)
• Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity — A. Gridnev, S. Maity, et al. (2022)
• Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors — P. Tiberio, E. Cavadini, et al. (2017)
• Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3 — M. Sun, H. Tang, et al. (2016)

Browse more research in JTCVS Open, or return to medical research.